Q-omics provides the consensus-scored ZNF707 profile across patient tissues and cancer cell-line models. ZNF707 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ZNF707 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, ZNF707 RNA expression shows 18,965 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, HNSC, and ACC as cancer lineages where ZNF707 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF707 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF707 survival associations across molecular data types. ZNF707 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF707 RNA expression–survival associations across cancer types. High ZNF707 expression shows unfavorable associations in UVM, KICH, ACC, KIRC, CESC and COAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for ZNF707 RNA expression.
This table summarizes ZNF707 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF707. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF707 shows higher tumor expression in HNSC, BLCA, COAD, LIHC, STAD and LUSC. The HNSC box plot shows higher ZNF707 RNA expression in tumor versus normal tissue (log2 FC = +1.305, t-test p < 0.001).
This table shows molecular features associated with ZNF707 in patient tissues and cancer cell lines. In patient samples, ZNF707 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF707 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LUNG_SCLC.
